| abstract |
The present invention relates generally to the treatment and diagnosis of diseases mediated by IL-5 and excess eosinophil production, and more particularly to mAbs, Fabs, chimeric and humanized antibodies. More particularly, a method is provided for lowering human eosinophils in need thereof, and the method comprises administering to said human a composition comprising at least one anti-IL-5 antibody. Wherein at least one anti-IL-5 antibody has an average maximum plasma concentration of about 1.03 ± 0.21 μg / mL, a value under the curve of about 15.5 ± 2.7 μg / day / mL, from about 16.2 ± 2.1 days to about 21.7 Provides a serum half-life of ± 2.8 days. |